{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:17:47Z","timestamp":1791285467443,"version":"4.1.0"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41581-024-00818-0","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T05:02:53Z","timestamp":1709614973000},"page":"402-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes &amp; Kidney Working Group"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0954-6088","authenticated-orcid":false,"given":"Djalila","family":"Mekahli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-0745","authenticated-orcid":false,"given":"Roman-Ulrich","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matko","family":"Marlais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Wlodkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Haeberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta L\u00f3pez","family":"de Argumedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Breysem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Fladrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-6699","authenticated-orcid":false,"given":"Elizabeth P.","family":"Henske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-8621","authenticated-orcid":false,"given":"Peter","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Jouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Christopher","family":"Kingswood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Lattouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8956-0324","authenticated-orcid":false,"given":"Marc","family":"Lilien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Maleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Siemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Devuyst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5668-5219","authenticated-orcid":false,"given":"David J.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rouvi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9685-9183","authenticated-orcid":false,"given":"John","family":"Bissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"818_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ajmg.c.31654","volume":"178","author":"JJ Bissler","year":"2018","unstructured":"Bissler, J. J. & Christopher Kingswood, J. Renal manifestation of tuberous sclerosis complex. Am. J. Med. Genet. C Semin. Med. Genet. 178, 338\u2013347 (2018).","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"818_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino, P. B., Nathanson, K. L. & Henske, E. P. The tuberous sclerosis complex. N. Engl. J. Med. 355, 1345\u20131356 (2006).","journal-title":"N. Engl. J. Med."},{"key":"818_CR3","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/sj.ejhg.5201625","volume":"14","author":"JR Yates","year":"2006","unstructured":"Yates, J. R. Tuberous sclerosis. Eur. J. Hum. Genet. 14, 1065\u20131073 (2006).","journal-title":"Eur. J. Hum. Genet."},{"key":"818_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/ndt\/gfy063","volume":"34","author":"JC Kingswood","year":"2019","unstructured":"Kingswood, J. C. et al. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease awareness. Nephrol. Dial. Transpl. 34, 502\u2013508 (2019).","journal-title":"Nephrol. Dial. Transpl."},{"key":"818_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1258-3","volume":"15","author":"JP Zollner","year":"2020","unstructured":"Zollner, J. P. et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J. Rare Dis. 15, 23 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"818_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/1756287216641353","volume":"8","author":"JJ Bissler","year":"2016","unstructured":"Bissler, J. J. & Kingswood, J. C. Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review. Ther. Adv. Urol. 8, 279\u2013290 (2016).","journal-title":"Ther. Adv. Urol."},{"key":"818_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S0025-6196(12)61196-3","volume":"66","author":"CW Shepherd","year":"1991","unstructured":"Shepherd, C. W., Gomez, M. R., Lie, J. T. & Crowson, C. S. Causes of death in patients with tuberous sclerosis. Mayo Clin. Proc. 66, 792\u2013796 (1991).","journal-title":"Mayo Clin. Proc."},{"key":"818_CR8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/dmcn.13352","volume":"59","author":"S Amin","year":"2017","unstructured":"Amin, S. et al. Causes of mortality in individuals with tuberous sclerosis complex. Dev. Med. Child Neurol. 59, 612\u2013617 (2017).","journal-title":"Dev. Med. Child Neurol."},{"key":"818_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0022-5347(01)63072-6","volume":"160","author":"DH Ewalt","year":"1998","unstructured":"Ewalt, D. H., Sheffield, E., Sparagana, S. P., Delgado, M. R. & Roach, E. S. Renal lesion growth in children with tuberous sclerosis complex. J. Urol. 160, 141\u2013145 (1998).","journal-title":"J. Urol."},{"key":"818_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.21037\/tp-20-150","volume":"9","author":"Z Xu","year":"2020","unstructured":"Xu, Z., Wu, J., Xu, G. & Luo, H. Abdominal ultrasonographic manifestations in pediatric patients with tuberous sclerosis complex. Transl. Pediatr. 9, 757\u2013767 (2020).","journal-title":"Transl. Pediatr."},{"key":"818_CR11","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/s41436-020-0823-4","volume":"22","author":"B Ogorek","year":"2020","unstructured":"Ogorek, B. et al. TSC2 pathogenic variants are predictive of severe clinical manifestations in TSC infants: results of the EPISTOP study. Genet. Med. 22, 1489\u20131497 (2020).","journal-title":"Genet. Med."},{"key":"818_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/ckj\/sft162","volume":"7","author":"S Korula","year":"2014","unstructured":"Korula, S. et al. Renal manifestations of tuberous sclerosis among children: an Indian experience and review of the literature. Clin. Kidney J. 7, 134\u2013137 (2014).","journal-title":"Clin. Kidney J."},{"key":"818_CR13","first-page":"436","volume":"107","author":"D Di Pinto","year":"2009","unstructured":"Di Pinto, D., Balestracci, A. & Delgado, N. Renal manifestations of tuberous sclerosis in children [Spanish]. Arch. Argent. Pediatr. 107, 436\u2013440 (2009).","journal-title":"Arch. Argent. Pediatr."},{"key":"818_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.braindev.2013.05.006","volume":"36","author":"RR Mettin","year":"2014","unstructured":"Mettin, R. R. et al. Wide spectrum of clinical manifestations in children with tuberous sclerosis complex \u2014 follow-up of 20 children. Brain Dev. 36, 306\u2013314 (2014).","journal-title":"Brain Dev."},{"key":"818_CR15","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1053\/j.ajkd.2015.05.016","volume":"66","author":"MJ Eijkemans","year":"2015","unstructured":"Eijkemans, M. J. et al. Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands. Am. J. Kidney Dis. 66, 638\u2013645 (2015).","journal-title":"Am. J. Kidney Dis."},{"key":"818_CR16","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3389\/fneur.2020.00972","volume":"11","author":"JC Kingswood","year":"2020","unstructured":"Kingswood, J. C. et al. Renal manifestations of tuberous sclerosis complex: key findings from the final analysis of the TOSCA study focussing mainly on renal angiomyolipomas. Front. Neurol. 11, 972 (2020).","journal-title":"Front. Neurol."},{"key":"818_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.juro.2016.09.082","volume":"197","author":"JC Warncke","year":"2017","unstructured":"Warncke, J. C. et al. Pediatric renal angiomyolipomas in tuberous sclerosis complex. J. Urol. 197, 500\u2013506 (2017).","journal-title":"J. Urol."},{"key":"818_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","volume":"123","author":"H Northrup","year":"2021","unstructured":"Northrup, H. et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr. Neurol. 123, 50\u201366 (2021).","journal-title":"Pediatr. Neurol."},{"key":"818_CR19","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140\u2013151 (2008).","journal-title":"N. Engl. J. Med."},{"key":"818_CR20","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler, J. J. et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381, 817\u2013824 (2013).","journal-title":"Lancet"},{"key":"818_CR21","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13983","volume":"7","author":"JJ Bissler","year":"2019","unstructured":"Bissler, J. J. et al. Tuberous sclerosis complex exhibits a new renal cystogenic mechanism. Physiol. Rep. 7, e13983 (2019).","journal-title":"Physiol. Rep."},{"key":"818_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan \u2014 a web and mobile app for systematic reviews. Syst. Rev. 5, 210 (2016).","journal-title":"Syst. Rev."},{"key":"818_CR23","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1542\/peds.2004-1260","volume":"114","author":"American Academy of Pediatrics Steering Committee on Quality Improvement and Management.","year":"2004","unstructured":"American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. Pediatrics 114, 874\u2013877 (2004).","journal-title":"Pediatrics"},{"key":"818_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev-genom-083118-015354","volume":"20","author":"CL Salussolia","year":"2019","unstructured":"Salussolia, C. L., Klonowska, K., Kwiatkowski, D. J. & Sahin, M. Genetic etiologies, diagnosis, and treatment of tuberous sclerosis complex. Annu. Rev. Genomics Hum. Genet. 20, 217\u2013240 (2019).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"818_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"818_CR26","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1038\/s41436-019-0562-6","volume":"21","author":"K Giannikou","year":"2019","unstructured":"Giannikou, K. et al. Low-level mosaicism in tuberous sclerosis complex: prevalence, clinical features, and risk of disease transmission. Genet. Med. 21, 2639\u20132643 (2019).","journal-title":"Genet. Med."},{"key":"818_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005637","volume":"11","author":"ME Tyburczy","year":"2015","unstructured":"Tyburczy, M. E. et al. Mosaic and intronic mutations in TSC1\/TSC2 explain the majority of TSC patients with no mutation identified by conventional testing. PLoS Genet. 11, e1005637 (2015).","journal-title":"PLoS Genet."},{"key":"818_CR28","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1038\/s41436-019-0520-3","volume":"21","author":"AM Treichel","year":"2019","unstructured":"Treichel, A. M. et al. Phenotypic distinctions between mosaic forms of tuberous sclerosis complex. Genet. Med. 21, 2594\u20132604 (2019).","journal-title":"Genet. Med."},{"key":"818_CR29","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ajhg.2023.04.002","volume":"110","author":"K Klonowska","year":"2023","unstructured":"Klonowska, K. et al. Comprehensive genetic and phenotype analysis of 95 individuals with mosaic tuberous sclerosis complex. Am. J. Hum. Genet. 110, 979\u2013988 (2023).","journal-title":"Am. J. Hum. Genet."},{"key":"818_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.kint.2019.11.019","volume":"97","author":"O Devuyst","year":"2020","unstructured":"Devuyst, O. & Pei, Y. Next-generation sequencing for detection of somatic mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. 97, 261\u2013263 (2020).","journal-title":"Kidney Int."},{"key":"818_CR31","first-page":"235","volume":"182","author":"AM Treichel","year":"2020","unstructured":"Treichel, A. M., Kwiatkowski, D. J., Moss, J. & Darling, T. N. A diagnostic algorithm for enhanced detection of mosaic tuberous sclerosis complex in adults. Br. J. Dermatol. 182, 235\u2013237 (2020).","journal-title":"Br. J. Dermatol."},{"key":"818_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00439-006-0308-9","volume":"121","author":"P Kozlowski","year":"2007","unstructured":"Kozlowski, P. et al. Identification of 54 large deletions\/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum. Genet. 121, 389\u2013400 (2007).","journal-title":"Hum. Genet."},{"key":"818_CR33","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1086\/514888","volume":"61","author":"JR Sampson","year":"1997","unstructured":"Sampson, J. R. et al. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am. J. Hum. Genet. 61, 843\u2013851 (1997).","journal-title":"Am. J. Hum. Genet."},{"key":"818_CR34","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1177\/0883073807307093","volume":"22","author":"DA Lyczkowski","year":"2007","unstructured":"Lyczkowski, D. A. et al. Intrafamilial phenotypic variability in tuberous sclerosis complex. J. Child Neurol. 22, 1348\u20131355 (2007).","journal-title":"J. Child Neurol."},{"key":"818_CR35","unstructured":"Northrup, H., et al. (University of Washington, Seattle Copyright \u00a9 1993-2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved., 1993)."},{"key":"818_CR36","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1086\/302381","volume":"64","author":"AC Jones","year":"1999","unstructured":"Jones, A. C. et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am. J. Hum. Genet. 64, 1305\u20131315 (1999).","journal-title":"Am. J. Hum. Genet."},{"key":"818_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/GIM.0b013e31803068c7","volume":"9","author":"KS Au","year":"2007","unstructured":"Au, K. S. et al. Genotype\/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet. Med. 9, 88\u2013100 (2007).","journal-title":"Genet. Med."},{"key":"818_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1086\/316951","volume":"68","author":"SL Dabora","year":"2001","unstructured":"Dabora, S. L. et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 68, 64\u201380 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"818_CR39","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/sj.ejhg.5201402","volume":"13","author":"O Sancak","year":"2005","unstructured":"Sancak, O. et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype \u2014 phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur. J. Hum. Genet. 13, 731\u2013741 (2005).","journal-title":"Eur. J. Hum. Genet."},{"key":"818_CR40","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/epi.12680","volume":"55","author":"SV Kothare","year":"2014","unstructured":"Kothare, S. V. et al. Severity of manifestations in tuberous sclerosis complex in relation to genotype. Epilepsia 55, 1025\u20131029 (2014).","journal-title":"Epilepsia"},{"key":"818_CR41","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/epi.12627","volume":"55","author":"SV Kothare","year":"2014","unstructured":"Kothare, S. V. et al. Genotype\/phenotype in tuberous sclerosis complex: associations with clinical and radiologic manifestations. Epilepsia 55, 1020\u20131024 (2014).","journal-title":"Epilepsia"},{"key":"818_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16988-w","volume":"7","author":"S Avgeris","year":"2017","unstructured":"Avgeris, S. et al. Mutational analysis of TSC1 and TSC2 genes in tuberous sclerosis complex patients from greece. Sci. Rep. 7, 16697 (2017).","journal-title":"Sci. Rep."},{"key":"818_CR43","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s11427-017-9091-x","volume":"60","author":"D Bai","year":"2017","unstructured":"Bai, D., Zhao, J., Li, L., Gao, J. & Wang, X. Analysis of genotypes and phenotypes in Chinese children with tuberous sclerosis complex. Sci. China Life Sci. 60, 763\u2013771 (2017).","journal-title":"Sci. China Life Sci."},{"key":"818_CR44","doi-asserted-by":"publisher","first-page":"170.e1","DOI":"10.1016\/j.urology.2016.10.056","volume":"101","author":"Y Cai","year":"2017","unstructured":"Cai, Y., Li, H. & Zhang, Y. Assessment of tuberous sclerosis complex associated with renal lesions by targeted next-generation sequencing in mainland China. Urology 101, 170.e1\u2013170.e7 (2017).","journal-title":"Urology"},{"key":"818_CR45","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.seizure.2019.08.010","volume":"71","author":"S Lin","year":"2019","unstructured":"Lin, S. et al. Tuberous sclerosis complex in Chinese patients: phenotypic analysis and mutational screening of TSC1\/TSC2 genes. Seizure 71, 322\u2013327 (2019).","journal-title":"Seizure"},{"key":"818_CR46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fgene.2020.00204","volume":"11","author":"Y Ding","year":"2020","unstructured":"Ding, Y. et al. Genotype and phenotype analysis of Chinese children with tuberous sclerosis complex: a pediatric cohort study. Front. Genet. 11, 204 (2020).","journal-title":"Front. Genet."},{"key":"818_CR47","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/cge.12920","volume":"91","author":"G Yang","year":"2017","unstructured":"Yang, G. et al. Phenotypic and genotypic characterization of Chinese children diagnosed with tuberous sclerosis complex. Clin. Genet. 91, 764\u2013768 (2017).","journal-title":"Clin. Genet."},{"key":"818_CR48","doi-asserted-by":"publisher","first-page":"11175","DOI":"10.3390\/ijms231911175","volume":"23","author":"S Togi","year":"2022","unstructured":"Togi, S., Ura, H., Hatanaka, H. & Niida, Y. Genotype and phenotype landscape of 283 Japanese patients with tuberous sclerosis complex. Int. J. Mol. Sci. 23, 11175 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"818_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185713","volume":"12","author":"C Rosset","year":"2017","unstructured":"Rosset, C. et al. Molecular analysis of TSC1 and TSC2 genes and phenotypic correlations in Brazilian families with tuberous sclerosis. PLoS One 12, e0185713 (2017).","journal-title":"PLoS One"},{"key":"818_CR50","doi-asserted-by":"publisher","first-page":"2329048x2110128","DOI":"10.1177\/2329048X211012817","volume":"8","author":"D Alsowat","year":"2021","unstructured":"Alsowat, D. et al. The phenotypic spectrum of tuberous sclerosis complex: a Canadian cohort. Child Neurol. Open 8, 2329048x211012817 (2021).","journal-title":"Child Neurol. Open"},{"key":"818_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-7-72","volume":"7","author":"CC Hung","year":"2006","unstructured":"Hung, C. C. et al. Molecular and clinical analyses of 84 patients with tuberous sclerosis complex. BMC Med. Genet. 7, 72 (2006).","journal-title":"BMC Med. Genet."},{"key":"818_CR52","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pediatrneurol.2019.03.003","volume":"96","author":"LS Farach","year":"2019","unstructured":"Farach, L. S. et al. Tuberous sclerosis complex genotypes and developmental phenotype. Pediatr. Neurol. 96, 58\u201363 (2019).","journal-title":"Pediatr. Neurol."},{"key":"818_CR53","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ajmg.a.38083","volume":"173","author":"LS Farach","year":"2017","unstructured":"Farach, L. S. et al. TSC2 c.1864C>T variant associated with mild cases of tuberous sclerosis complex. Am. J. Med. Genet. A 173, 771\u2013775 (2017).","journal-title":"Am. J. Med. Genet. A"},{"key":"818_CR54","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/jmg.38.5.347","volume":"38","author":"L Khare","year":"2001","unstructured":"Khare, L. et al. A novel missense mutation in the GTPase activating protein homology region of TSC2 in two large families with tuberous sclerosis complex. J. Med. Genet. 38, 347\u2013349 (2001).","journal-title":"J. Med. Genet."},{"key":"818_CR55","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ana.21037","volume":"60","author":"AC Jansen","year":"2006","unstructured":"Jansen, A. C. et al. Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation. Ann. Neurol. 60, 528\u2013539 (2006).","journal-title":"Ann. Neurol."},{"key":"818_CR56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejpn.2020.01.004","volume":"25","author":"HM Hulshof","year":"2020","unstructured":"Hulshof, H. M. et al. Counselling in tuberous sclerosis complex: a survey on content and satisfaction in the Netherlands. Eur. J. Paediatr. Neurol. 25, 113\u2013119 (2020).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"818_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1952","volume":"10","author":"XY Yang","year":"2022","unstructured":"Yang, X. Y. et al. Noninvasive prenatal diagnosis based on cell-free DNA for tuberous sclerosis: a pilot study. Mol. Genet. Genom. Med. 10, e1952 (2022).","journal-title":"Mol. Genet. Genom. Med."},{"key":"818_CR58","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/dmcn.15265","volume":"64","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Prenatal diagnosis and intervention improve developmental outcomes and epilepsy prognosis in children with tuberous sclerosis complex. Dev. Med. Child Neurol. 64, 1230\u20131236 (2022).","journal-title":"Dev. Med. Child Neurol."},{"key":"818_CR59","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.25956","volume":"89","author":"K Kotulska","year":"2021","unstructured":"Kotulska, K. et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann. Neurol. 89, 304\u2013314 (2021).","journal-title":"Ann. Neurol."},{"key":"818_CR60","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s00467-018-4003-6","volume":"33","author":"P Janssens","year":"2018","unstructured":"Janssens, P. et al. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. Pediatr. Nephrol. 33, 2085\u20132093 (2018).","journal-title":"Pediatr. Nephrol."},{"key":"818_CR61","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40620-020-00714-3","volume":"34","author":"E Vabret","year":"2021","unstructured":"Vabret, E., Couchoud, C., Lassalle, M. & Vigneau, C. From tuberous sclerosis complex to end stage renal disease: who are these patients? J. Nephrol. 34, 607\u2013615 (2021).","journal-title":"J. Nephrol."},{"key":"818_CR62","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1681\/ASN.V12122832","volume":"12","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti, P., Perna, A. & Remuzzi, G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J. Am. Soc. Nephrol. 12, 2832\u20132837 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"818_CR63","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2215\/CJN.07371009","volume":"5","author":"M Duerr","year":"2010","unstructured":"Duerr, M. et al. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 5, 703\u2013708 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"818_CR64","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","volume":"99","author":"AK Cheung","year":"2021","unstructured":"Cheung, A. K. et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 99, 559\u2013569 (2021).","journal-title":"Kidney Int."},{"key":"818_CR65","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams, B. et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 39, 3021\u20133104 (2018).","journal-title":"Eur. Heart J."},{"key":"818_CR66","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1097\/HJH.0000000000001039","volume":"34","author":"E Lurbe","year":"2016","unstructured":"Lurbe, E. et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J. Hypertens. 34, 1887\u20131920 (2016).","journal-title":"J. Hypertens."},{"key":"818_CR67","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-1904","volume":"140","author":"JT Flynn","year":"2017","unstructured":"Flynn, J. T. et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140, e20171904 (2017).","journal-title":"Pediatrics"},{"key":"818_CR68","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.phrs.2016.10.002","volume":"114","author":"RW Schrier","year":"2016","unstructured":"Schrier, R. W. ACE inhibitors, left ventricular mass and renal cyst growth in ADPKD. Pharmacol. Res. 114, 166\u2013168 (2016).","journal-title":"Pharmacol. Res."},{"key":"818_CR69","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.urology.2016.04.027","volume":"95","author":"J Bissler","year":"2016","unstructured":"Bissler, J. et al. Long-term clinical morbidity in patients with renal angiomyolipoma associated with tuberous sclerosis complex. Urology 95, 80\u201387 (2016).","journal-title":"Urology"},{"key":"818_CR70","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3111\/13696998.2015.1075995","volume":"18","author":"F Vekeman","year":"2015","unstructured":"Vekeman, F. et al. Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs. J. Med. Econ. 18, 1060\u20131070 (2015).","journal-title":"J. Med. Econ."},{"key":"818_CR71","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/IJNRD.S123638","volume":"10","author":"L Malaga-Dieguez","year":"2017","unstructured":"Malaga-Dieguez, L. et al. Early manifestations of renal disease in patients with tuberous sclerosis complex. Int. J. Nephrol. Renovasc. Dis. 10, 91\u201395 (2017).","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"818_CR72","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz, G. J. et al. New equations to estimate GFR in children with CKD. J. Am. Soc. Nephrol. 20, 629\u2013637 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"818_CR73","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1681\/ASN.2009080832","volume":"20","author":"PP Reese","year":"2009","unstructured":"Reese, P. P. & Feldman, H. I. More evidence that cystatin C predicts mortality better than creatinine. J. Am. Soc. Nephrol. 20, 2088\u20132090 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"818_CR74","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens, P. E. & Levin, A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158, 825\u2013830 (2013).","journal-title":"Ann. Intern. Med."},{"key":"818_CR75","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.urology.2019.09.035","volume":"135","author":"O Anis","year":"2020","unstructured":"Anis, O. et al. Selective arterial embolization for large or symptomatic renal angiomyolipoma: 10 years of follow-up. Urology 135, 82\u201387 (2020).","journal-title":"Urology"},{"key":"818_CR76","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1177\/0300060519834447","volume":"47","author":"L Lin","year":"2019","unstructured":"Lin, L. et al. Renal function, complications, and outcomes of a reduction in tumor size after transarterial embolization for renal angiomyolipomas: a meta-analysis. J. Int. Med. Res. 47, 1417\u20131428 (2019).","journal-title":"J. Int. Med. Res."},{"key":"818_CR77","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1053\/j.ajkd.2023.04.016","volume":"82","author":"J Kronick","year":"2023","unstructured":"Kronick, J., Gabril, M. Y. & House, A. A. Microscopic kidney disease in tuberous sclerosis complex and treatment with mTOR inhibition. Am. J. Kidney Dis. 82, 772\u2013775 (2023).","journal-title":"Am. J. Kidney Dis."},{"key":"818_CR78","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1615\/CritRevOncog.2022042857","volume":"27","author":"JJ Bissler","year":"2022","unstructured":"Bissler, J. J., Batchelor, D. & Kingswood, J. C. Progress in tuberous sclerosis complex renal disease. Crit. Rev. Oncog. 27, 35\u201349 (2022).","journal-title":"Crit. Rev. Oncog."},{"key":"818_CR79","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/ndt\/gfy132","volume":"34","author":"JJ Bissler","year":"2019","unstructured":"Bissler, J. J. et al. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Nephrol. Dial. Transpl. 34, 1000\u20131008 (2019).","journal-title":"Nephrol. Dial. Transpl."},{"key":"818_CR80","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1159\/000516911","volume":"46","author":"S Sharma","year":"2021","unstructured":"Sharma, S. & Smyth, B. From proteinuria to fibrosis: an update on pathophysiology and treatment options. Kidney Blood Press. Res. 46, 411\u2013420 (2021).","journal-title":"Kidney Blood Press. Res."},{"key":"818_CR81","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/ki.2012.225","volume":"82","author":"TA Ho","year":"2012","unstructured":"Ho, T. A. et al. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation. Kidney Int. 82, 1121\u20131129 (2012).","journal-title":"Kidney Int."},{"key":"818_CR82","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00467-017-3672-x","volume":"33","author":"P Janssens","year":"2018","unstructured":"Janssens, P. et al. Expanding the role of vasopressin antagonism in polycystic kidney diseases: from adults to children? Pediatr. Nephrol. 33, 395\u2013408 (2018).","journal-title":"Pediatr. Nephrol."},{"key":"818_CR83","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman, A. B. et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 88, 17\u201327 (2015).","journal-title":"Kidney Int."},{"key":"818_CR84","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s10157-012-0650-2","volume":"16","author":"T Suwabe","year":"2012","unstructured":"Suwabe, T. et al. Clinical features of cyst infection and hemorrhage in ADPKD: new diagnostic criteria. Clin. Exp. Nephrol. 16, 892\u2013902 (2012).","journal-title":"Clin. Exp. Nephrol."},{"key":"818_CR85","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1093\/ndt\/gfab040","volume":"37","author":"F Jouret","year":"2022","unstructured":"Jouret, F., Hogan, M. C. & Chebib, F. T. A practical guide for the management of acute abdominal pain with fever in patients with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transpl. 37, 1426\u20131428 (2022).","journal-title":"Nephrol. Dial. Transpl."},{"key":"818_CR86","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/diseases9020039","volume":"9","author":"P Acharya","year":"2021","unstructured":"Acharya, P. et al. Incidence and characteristics of kidney stones in patients on ketogenic diet: a systematic review and meta-analysis. Diseases 9, 39 (2021).","journal-title":"Diseases"},{"key":"818_CR87","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.nefro.2019.03.003","volume":"40","author":"ME Reyna-Fabi\u00e1n","year":"2020","unstructured":"Reyna-Fabi\u00e1n, M. E. et al. TSC2\/PKD1 contiguous gene syndrome, with emphasis on a case with an atypical mild polycystic kidney phenotype and a novel genetic variant. Nefrologia 40, 91\u201398 (2020).","journal-title":"Nefrologia"},{"key":"818_CR88","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/ndt\/12.11.2284","volume":"12","author":"MD Griffin","year":"1997","unstructured":"Griffin, M. D. et al. Neonatal presentation of autosomal dominant polycystic kidney disease with a maternal history of tuberous sclerosis. Nephrol. Dial. Transpl. 12, 2284\u20132288 (1997).","journal-title":"Nephrol. Dial. Transpl."},{"key":"818_CR89","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup, H., Krueger, D. A. & International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr. Neurol. 49, 243\u2013254 (2013).","journal-title":"Pediatr. Neurol."},{"key":"818_CR90","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.crad.2005.01.009","volume":"60","author":"U Patel","year":"2005","unstructured":"Patel, U., Simpson, E., Kingswood, J. C. & Saggar-Malik, A. K. Tuberose sclerosis complex: analysis of growth rates aids differentiation of renal cell carcinoma from atypical or minimal-fat-containing angiomyolipoma. Clin. Radiol. 60, 665\u2013673 (2005).","journal-title":"Clin. Radiol."},{"key":"818_CR91","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2214\/AJR.16.17530","volume":"209","author":"NA Avila","year":"2017","unstructured":"Avila, N. A., Dwyer, A. J. & Moss, J. Active surveillance of nonfatty renal masses in patients with lymphangioleiomyomatosis: use of CT features and patterns of growth to differentiate angiomyolipoma from renal cancer. AJR Am. J. Roentgenol. 209, 611\u2013619 (2017).","journal-title":"AJR Am. J. Roentgenol."},{"key":"818_CR92","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.juro.2008.05.041","volume":"180","author":"BR Lane","year":"2008","unstructured":"Lane, B. R. et al. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. J. Urol. 180, 836\u2013843 (2008).","journal-title":"J. Urol."},{"key":"818_CR93","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2214\/AJR.14.14255","volume":"205","author":"RA Rabenou","year":"2015","unstructured":"Rabenou, R. A. & Charles, H. W. Differentiation of sporadic versus tuberous sclerosis complex-associated angiomyolipoma. AJR Am. J. Roentgenol. 205, 292\u2013301 (2015).","journal-title":"AJR Am. J. Roentgenol."},{"key":"818_CR94","first-page":"e15","volume":"118","author":"BP Dixon","year":"2011","unstructured":"Dixon, B. P., Hulbert, J. C. & Bissler, J. J. Tuberous sclerosis complex renal disease. Nephron 118, e15\u2013e20 (2011).","journal-title":"Nephron"},{"key":"818_CR95","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3349\/ymj.2010.51.5.728","volume":"51","author":"KC Koo","year":"2010","unstructured":"Koo, K. C. et al. Trends of presentation and clinical outcome of treated renal angiomyolipoma. Yonsei Med. J. 51, 728\u2013734 (2010).","journal-title":"Yonsei Med. J."},{"key":"818_CR96","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.diii.2013.01.003","volume":"94","author":"O Rouviere","year":"2013","unstructured":"Rouviere, O., Nivet, H., Grenier, N., Zini, L. & Lechevallier, E. Kidney damage due to tuberous sclerosis complex: management recommendations. Diagn. Interv. Imaging 94, 225\u2013237 (2013).","journal-title":"Diagn. Interv. Imaging"},{"key":"818_CR97","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/ckj\/sfx094","volume":"10","author":"MJ Buj Pradilla","year":"2017","unstructured":"Buj Pradilla, M. J., Marti Balleste, T., Torra, R. & Villacampa Auba, F. Recommendations for imaging-based diagnosis and management of renal angiomyolipoma associated with tuberous sclerosis complex. Clin. Kidney J. 10, 728\u2013737 (2017).","journal-title":"Clin. Kidney J."},{"key":"818_CR98","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1053\/j.sult.2016.11.001","volume":"38","author":"M Jinzaki","year":"2017","unstructured":"Jinzaki, M., Silverman, S. G., Akita, H., Mikami, S. & Oya, M. Diagnosis of renal angiomyolipomas: classic, fat-poor, and epithelioid types. Semin. Ultrasound CT MR 38, 37\u201346 (2017).","journal-title":"Semin. Ultrasound CT MR"},{"key":"818_CR99","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s00467-020-04835-6","volume":"36","author":"JP Chan","year":"2021","unstructured":"Chan, J. P. et al. Utility of contrast-enhanced ultrasound for solid mass surveillance and characterization in children with tuberous sclerosis complex: an initial experience. Pediatr. Nephrol. 36, 1775\u20131784 (2021).","journal-title":"Pediatr. Nephrol."},{"key":"818_CR100","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.diii.2015.12.004","volume":"97","author":"J Champagnac","year":"2016","unstructured":"Champagnac, J. et al. Microaneurysms in renal angiomyolipomas: can clinical and computed tomography features predict their presence and size? Diagn. Interv. Imaging 97, 321\u2013326 (2016).","journal-title":"Diagn. Interv. Imaging"},{"key":"818_CR101","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.mric.2020.03.008","volume":"28","author":"MT Heller","year":"2020","unstructured":"Heller, M. T., Furlan, A. & Kawashima, A. Multiparametric MR for solid renal mass characterization. Magn. Reson. Imaging Clin. N. Am. 28, 457\u2013469 (2020).","journal-title":"Magn. Reson. Imaging Clin. N. Am."},{"key":"818_CR102","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1148\/radiol.211680","volume":"303","author":"N Schieda","year":"2022","unstructured":"Schieda, N. et al. Multicenter evaluation of multiparametric MRI clear cell likelihood scores in solid indeterminate small renal masses. Radiology 303, 590\u2013599 (2022).","journal-title":"Radiology"},{"key":"818_CR103","first-page":"281","volume":"49","author":"M Dickinson","year":"1998","unstructured":"Dickinson, M., Ruckle, H., Beaghler, M. & Hadley, H. R. Renal angiomyolipoma: optimal treatment based on size and symptoms. Clin. Nephrol. 49, 281\u2013286 (1998).","journal-title":"Clin. Nephrol."},{"key":"818_CR104","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/21681805.2020.1716066","volume":"54","author":"J Sward","year":"2020","unstructured":"Sward, J., Henrikson, O., Lyrdal, D., Peeker, R. & Lundstam, S. Renal angiomyolipoma-patient characteristics and treatment with focus on active surveillance. Scand. J. Urol. 54, 141\u2013146 (2020).","journal-title":"Scand. J. Urol."},{"key":"818_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-015-0118-2","volume":"15","author":"T Kuusk","year":"2015","unstructured":"Kuusk, T. et al. Treatment of renal angiomyolipoma: pooled analysis of individual patient data. BMC Urol. 15, 123 (2015).","journal-title":"BMC Urol."},{"key":"818_CR106","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jfma.2018.02.012","volume":"118","author":"KH Lee","year":"2019","unstructured":"Lee, K. H. et al. Clinical behavior and management of three types of renal angiomyolipomas. J. Formos. Med. Assoc. 118, 162\u2013169 (2019).","journal-title":"J. Formos. Med. Assoc."},{"key":"818_CR107","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger, D. A., Northrup, H. & International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr. Neurol. 49, 255\u2013265 (2013).","journal-title":"Pediatr. Neurol."},{"key":"818_CR108","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11255-017-1766-9","volume":"50","author":"JLH Ruud Bosch","year":"2018","unstructured":"Ruud Bosch, J. L. H. et al. Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center. Int. Urol. Nephrol. 50, 459\u2013467 (2018).","journal-title":"Int. Urol. Nephrol."},{"key":"818_CR109","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0022-5347(05)64440-0","volume":"168","author":"CP Nelson","year":"2002","unstructured":"Nelson, C. P. & Sanda, M. G. Contemporary diagnosis and management of renal angiomyolipoma. J. Urol. 168, 1315\u20131325 (2002).","journal-title":"J. Urol."},{"key":"818_CR110","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020167","volume":"99","author":"XF Xu","year":"2020","unstructured":"Xu, X. F. et al. A scoring system based on clinical features for the prediction of sporadic renal angiomyolipoma rupture and hemorrhage. Medicine 99, e20167 (2020).","journal-title":"Medicine"},{"key":"818_CR111","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/S0221-0363(06)74166-X","volume":"87","author":"C Dabbeche","year":"2006","unstructured":"Dabbeche, C. et al. Role of embolization in renal angiomyolipomas [French]. J. Radiol. 87, 1859\u20131867 (2006).","journal-title":"J. Radiol."},{"key":"818_CR112","volume":"14","author":"M Zeid","year":"2022","unstructured":"Zeid, M. et al. Active surveillance for renal angiomyolipoma less than 4 centimeters: a systematic review of cohort studies. Cureus 14, e22678 (2022).","journal-title":"Cureus"},{"key":"818_CR113","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.urology.2017.02.023","volume":"104","author":"I Cockerell","year":"2017","unstructured":"Cockerell, I. et al. Prevalence of renal angiomyolipomas and spontaneous bleeding related to angiomyolipomas in tuberous sclerosis complex patients in France and Norway \u2014 a questionnaire study. Urology 104, 70\u201376 (2017).","journal-title":"Urology"},{"key":"818_CR114","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.eururo.2016.01.048","volume":"70","author":"JR Bhatt","year":"2016","unstructured":"Bhatt, J. R. et al. Natural history of renal angiomyolipoma (AML): most patients with large AMLs >4cm can be offered active surveillance as an initial management strategy. Eur. Urol. 70, 85\u201390 (2016).","journal-title":"Eur. Urol."},{"key":"818_CR115","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bju.12604","volume":"114","author":"I Ouzaid","year":"2014","unstructured":"Ouzaid, I. et al. Active surveillance for renal angiomyolipoma: outcomes and factors predictive of delayed intervention. BJU Int. 114, 412\u2013417 (2014).","journal-title":"BJU Int."},{"key":"818_CR116","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1148\/radiol.2251011477","volume":"225","author":"K Yamakado","year":"2002","unstructured":"Yamakado, K. et al. Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 225, 78\u201382 (2002).","journal-title":"Radiology"},{"key":"818_CR117","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.crad.2006.02.003","volume":"61","author":"U Rimon","year":"2006","unstructured":"Rimon, U. et al. Large renal angiomyolipomas: digital subtraction angiographic grading and presentation with bleeding. Clin. Radiol. 61, 520\u2013526 (2006).","journal-title":"Clin. Radiol."},{"key":"818_CR118","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12882-018-0835-3","volume":"19","author":"I Cockerell","year":"2018","unstructured":"Cockerell, I. et al. Renal manifestations of tuberous sclerosis complex: patients\u2019 and parents\u2019 knowledge and routines for renal follow-up \u2014 a questionnaire study. BMC Nephrol. 19, 39 (2018).","journal-title":"BMC Nephrol."},{"key":"818_CR119","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2020.12.008","volume":"117","author":"AM Goedken","year":"2021","unstructured":"Goedken, A. M., Samuels, J. A., Sato, T. S. & Harshman, L. A. Kidney imaging surveillance in commercially insured patients with tuberous sclerosis complex. Pediatr. Neurol. 117, 21\u201326 (2021).","journal-title":"Pediatr. Neurol."},{"key":"818_CR120","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s11255-014-0701-6","volume":"46","author":"JD Tsai","year":"2014","unstructured":"Tsai, J. D., Wei, C. C., Chen, S. M., Lue, K. H. & Sheu, J. N. Association between the growth rate of renal cysts\/angiomyolipomas and age in the patients with tuberous sclerosis complex. Int. Urol. Nephrol. 46, 1685\u20131690 (2014).","journal-title":"Int. Urol. Nephrol."},{"key":"818_CR121","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.ki.5001853","volume":"70","author":"SK Rakowski","year":"2006","unstructured":"Rakowski, S. K. et al. Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int. 70, 1777\u20131782 (2006).","journal-title":"Kidney Int."},{"key":"818_CR122","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11547-015-0572-7","volume":"121","author":"A Robert","year":"2016","unstructured":"Robert, A. et al. Renal involvement in tuberous sclerosis complex with emphasis on cystic lesions. Radiol. Med. 121, 402\u2013408 (2016).","journal-title":"Radiol. Med."},{"key":"818_CR123","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/S0022-5347(05)64608-3","volume":"168","author":"TS Lendvay","year":"2002","unstructured":"Lendvay, T. S., Broecker, B. & Smith, E. A. Renal cell carcinoma in a 2-year-old child with tuberous sclerosis. J. Urol. 168, 1131\u20131132 (2002).","journal-title":"J. Urol."},{"key":"818_CR124","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1148\/radiographics.19.5.g99se231388","volume":"19","author":"JW Allison","year":"1999","unstructured":"Allison, J. W., James, C. A. & Figarola, M. S. Pediatric case of the day. Renal cell carcinoma in a child with tuberous sclerosis. Radiographics 19, 1388\u20131389 (1999).","journal-title":"Radiographics"},{"key":"818_CR125","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2208::AID-CNCR21>3.0.CO;2-K","volume":"83","author":"T Al-Saleem","year":"1998","unstructured":"Al-Saleem, T. et al. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 83, 2208\u20132216 (1998).","journal-title":"Cancer"},{"key":"818_CR126","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1097\/PAS.0000000000000248","volume":"38","author":"J Guo","year":"2014","unstructured":"Guo, J. et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am. J. Surg. Pathol. 38, 1457\u20131467 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"818_CR127","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00247-002-0765-9","volume":"32","author":"L Breysem","year":"2002","unstructured":"Breysem, L., Nijs, E., Proesmans, W. & Smet, M. H. Tuberous sclerosis with cystic renal disease and multifocal renal cell carcinoma in a baby girl. Pediatr. Radiol. 32, 677\u2013680 (2002).","journal-title":"Pediatr. Radiol."},{"key":"818_CR128","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/ajmg.a.37644","volume":"170","author":"A Peron","year":"2016","unstructured":"Peron, A. et al. Do patients with tuberous sclerosis complex have an increased risk for malignancies? Am. J. Med. Genet. A 170, 1538\u20131544 (2016).","journal-title":"Am. J. Med. Genet. A"},{"key":"818_CR129","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3390\/genes12101585","volume":"12","author":"EP Henske","year":"2021","unstructured":"Henske, E. P., Cornejo, K. M. & Wu, C. L. Renal cell carcinoma in tuberous sclerosis complex. Genes 12, 1585 (2021).","journal-title":"Genes"},{"key":"818_CR130","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/PAS.0000000000000237","volume":"38","author":"P Yang","year":"2014","unstructured":"Yang, P. et al. Renal cell carcinoma in tuberous sclerosis complex. Am. J. Surg. Pathol. 38, 895\u2013909 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"818_CR131","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1093\/hmg\/ddu597","volume":"24","author":"ME Tyburczy","year":"2015","unstructured":"Tyburczy, M. E. et al. A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex. Hum. Mol. Genet. 24, 1836\u20131842 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"818_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01917-y","volume":"16","author":"M Sauter","year":"2021","unstructured":"Sauter, M. et al. Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA). Orphanet J. Rare Dis. 16, 301 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"818_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0151-3","volume":"9","author":"ZW Yeoh","year":"2014","unstructured":"Yeoh, Z. W. et al. Natural history of angiomyolipoma in lymphangioleiomyomatosis: implications for screening and surveillance. Orphanet J. Rare Dis. 9, 151 (2014).","journal-title":"Orphanet J. Rare Dis."},{"key":"818_CR134","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2217\/thy.11.32","volume":"8","author":"C Battelli","year":"2011","unstructured":"Battelli, C. & Cho, D. C. mTOR inhibitors in renal cell carcinoma. Therapy 8, 359\u2013367 (2011).","journal-title":"Therapy"},{"key":"818_CR135","first-page":"Cd011272","volume":"7","author":"TH Sasongko","year":"2016","unstructured":"Sasongko, T. H., Ismail, N. F. & Zabidi-Hussin, Z. Rapamycin and rapalogs for tuberous sclerosis complex. Cochrane Database Syst. Rev. 7, Cd011272 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"818_CR136","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.urology.2017.02.036","volume":"104","author":"E Swallow","year":"2017","unstructured":"Swallow, E. et al. Patterns of disease monitoring and treatment among patients with tuberous sclerosis complex-related angiomyolipomas. Urology 104, 110\u2013114 (2017).","journal-title":"Urology"},{"key":"818_CR137","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfv249","volume":"31","author":"JJ Bissler","year":"2016","unstructured":"Bissler, J. J. et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol. Dial. Transpl. 31, 111\u2013119 (2016).","journal-title":"Nephrol. Dial. Transpl."},{"key":"818_CR138","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jpeds.2017.05.015","volume":"187","author":"BJ Siroky","year":"2017","unstructured":"Siroky, B. J. et al. Improvement in renal cystic disease of tuberous sclerosis complex after treatment with mammalian target of rapamycin inhibitor. J. Pediatr. 187, 318\u2013322.e2 (2017).","journal-title":"J. Pediatr."},{"key":"818_CR139","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/ndt\/gfu013","volume":"29","author":"JC Kingswood","year":"2014","unstructured":"Kingswood, J. C. et al. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, phase 3 trial EXIST-1. Nephrol. Dial. Transpl. 29, 1203\u20131210 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"818_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87930-4","volume":"11","author":"EH Watanabe","year":"2021","unstructured":"Watanabe, E. H. et al. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures. Sci. Rep. 11, 8493 (2021).","journal-title":"Sci. Rep."},{"key":"818_CR141","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s11255-019-02093-6","volume":"51","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex. Int. Urol. Nephrol. 51, 671\u2013676 (2019).","journal-title":"Int. Urol. Nephrol."},{"key":"818_CR142","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s10147-018-1325-0","volume":"23","author":"T Hatano","year":"2018","unstructured":"Hatano, T. et al. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization. Int. J. Clin. Oncol. 23, 1134\u20131139 (2018).","journal-title":"Int. J. Clin. Oncol."},{"key":"818_CR143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189132","volume":"12","author":"S Brakemeier","year":"2017","unstructured":"Brakemeier, S. et al. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC). PLoS One 12, e0189132 (2017).","journal-title":"PLoS One"},{"key":"818_CR144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204646","volume":"13","author":"BA Zonnenberg","year":"2018","unstructured":"Zonnenberg, B. A. et al. Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus. PLoS One 13, e0204646 (2018).","journal-title":"PLoS One"},{"key":"818_CR145","first-page":"iii43","volume":"29","author":"JJ Bissler","year":"2014","unstructured":"Bissler, J. J. et al. Effect of everolimus on renal function in patients with tuberous sclerosis complex (TSC): results from exist-1 and exist-2. Nephrol. Dial. Transplant. 29, iii43\u2013iii44 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"818_CR146","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/bcp.12834","volume":"81","author":"K Budde","year":"2016","unstructured":"Budde, K. et al. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. Br. J. Clin. Pharmacol. 81, 958\u2013970 (2016).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"818_CR147","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00467-017-3806-1","volume":"33","author":"JJ Bissler","year":"2018","unstructured":"Bissler, J. J. et al. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatr. Nephrol. 33, 101\u2013109 (2018).","journal-title":"Pediatr. Nephrol."},{"key":"818_CR148","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/iju.13168","volume":"23","author":"T Hatano","year":"2016","unstructured":"Hatano, T., Chikaraishi, K., Inaba, H., Endo, K. & Egawa, S. Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: a single institution experience in Japan. Int. J. Urol. 23, 833\u2013838 (2016).","journal-title":"Int. J. Urol."},{"key":"818_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0517-9","volume":"11","author":"NR Robles","year":"2016","unstructured":"Robles, N. R. et al. Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial. Orphanet J. Rare Dis. 11, 128 (2016).","journal-title":"Orphanet J. Rare Dis."},{"key":"818_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0781-y","volume":"13","author":"Y Cai","year":"2018","unstructured":"Cai, Y. et al. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Orphanet J. Rare Dis. 13, 43 (2018).","journal-title":"Orphanet J. Rare Dis."},{"key":"818_CR151","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.urology.2019.12.041","volume":"139","author":"CQ Wu","year":"2020","unstructured":"Wu, C. Q., Wolf, D. S. & Smith, E. A. Fate of pediatric renal angiomyolipoma during mTOR inhibitor treatment in tuberous sclerosis complex. Urology 139, 161\u2013167 (2020).","journal-title":"Urology"},{"key":"818_CR152","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10147-020-01792-w","volume":"26","author":"T Hatano","year":"2021","unstructured":"Hatano, T., Endo, K. & Tamari, M. Efficacy and safety of low-dose everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex. Int. J. Clin. Oncol. 26, 163\u2013168 (2021).","journal-title":"Int. J. Clin. Oncol."},{"key":"818_CR153","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/iju.13428","volume":"24","author":"T Hatano","year":"2017","unstructured":"Hatano, T., Inaba, H., Endo, K. & Egawa, S. Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex. Int. J. Urol. 24, 780\u2013785 (2017).","journal-title":"Int. J. Urol."},{"key":"818_CR154","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-87","volume":"7","author":"C Cabrera-L\u00f3pez","year":"2012","unstructured":"Cabrera-L\u00f3pez, C. et al. Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial. Orphanet J. Rare Dis. 7, 87 (2012).","journal-title":"Orphanet J. Rare Dis."},{"key":"818_CR155","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","volume":"17","author":"DM Davies","year":"2011","unstructured":"Davies, D. M. et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin. Cancer Res. 17, 4071\u20134081 (2011).","journal-title":"Clin. Cancer Res."},{"key":"818_CR156","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180939","volume":"12","author":"JJ Bissler","year":"2017","unstructured":"Bissler, J. J. et al. Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. PLoS One 12, e0180939 (2017).","journal-title":"PLoS One"},{"key":"818_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(15)60004-5","volume":"14","author":"JJ Bissler","year":"2015","unstructured":"Bissler, J. J. et al. Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex (TSC) from EXIST-2: continued efficacy and diminishing adverse events after ~3.5 years of treatment. Eur. Urol. Suppl. 14, e1 (2015).","journal-title":"Eur. Urol. Suppl."},{"key":"818_CR158","doi-asserted-by":"publisher","first-page":"e981","DOI":"10.1016\/S1569-9056(13)61459-1","volume":"12","author":"K Budde","year":"2013","unstructured":"Budde, K. et al. Predictive value of angiogenic biomarkers in tuberous sclerosis complex (TSC) patients with renal angiomyolipoma (AML). Eur. Urol. Suppl. 12, e981\u2013e982 (2013).","journal-title":"Eur. Urol. Suppl."},{"key":"818_CR159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201005","volume":"13","author":"JJ Bissler","year":"2018","unstructured":"Bissler, J. J. et al. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. PLoS One 13, e0201005 (2018).","journal-title":"PLoS One"},{"key":"818_CR160","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S1522-1865(03)00121-5","volume":"4","author":"R Waksman","year":"2003","unstructured":"Waksman, R. et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc. Radiat. Med. 4, 34\u201338 (2003).","journal-title":"Cardiovasc. Radiat. Med."},{"key":"818_CR161","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/01.fjc.0000177985.14305.15","volume":"46","author":"R Pakala","year":"2005","unstructured":"Pakala, R., Stabile, E., Jang, G. J., Clavijo, L. & Waksman, R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J. Cardiovasc. Pharmacol. 46, 481\u2013486 (2005).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"818_CR162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158476","volume":"11","author":"DN Franz","year":"2016","unstructured":"Franz, D. N. et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS One 11, e0158476 (2016).","journal-title":"PLoS One"},{"key":"818_CR163","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S1\u2013S197 (2024).","journal-title":"Kidney Int."},{"key":"818_CR164","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/jcph.428","volume":"55","author":"MJ Somers","year":"2015","unstructured":"Somers, M. J. & Paul, E. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation. J. Clin. Pharmacol. 55, 368\u2013376 (2015).","journal-title":"J. Clin. Pharmacol."},{"key":"818_CR165","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jdv.14964","volume":"32","author":"DN Franz","year":"2018","unstructured":"Franz, D. N. et al. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies. J. Eur. Acad. Dermatol. Venereol. 32, 1796\u20131803 (2018).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"818_CR166","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.euo.2019.04.005","volume":"3","author":"S Fern\u00e1ndez-Pello","year":"2020","unstructured":"Fern\u00e1ndez-Pello, S. et al. Management of sporadic renal angiomyolipomas: a systematic review of available evidence to guide recommendations from the European Association of Urology renal cell carcinoma guidelines panel. Eur. Urol. Oncol. 3, 57\u201372 (2020).","journal-title":"Eur. Urol. Oncol."},{"key":"818_CR167","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.crad.2008.02.005","volume":"63","author":"J Lenton","year":"2008","unstructured":"Lenton, J., Kessel, D. & Watkinson, A. F. Embolization of renal angiomyolipoma: immediate complications and long-term outcomes. Clin. Radiol. 63, 864\u2013870 (2008).","journal-title":"Clin. Radiol."},{"key":"818_CR168","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1464-410X.2007.07059.x","volume":"100","author":"TL Danforth","year":"2007","unstructured":"Danforth, T. L., Lane, B. R. & Novick, A. C. Conservative management of giant symptomatic angiomyolipomas in patients with the tuberous sclerosis complex. BJU Int. 100, 794\u2013797 (2007).","journal-title":"BJU Int."},{"key":"818_CR169","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/01.AOG.0000167392.59472.c3","volume":"107","author":"DW Storm","year":"2006","unstructured":"Storm, D. W. & Mowad, J. J. Conservative management of a bleeding renal angiomyolipoma in pregnancy. Obstet. Gynecol. 107, 490\u2013492 (2006).","journal-title":"Obstet. Gynecol."},{"key":"818_CR170","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1159\/000515990","volume":"105","author":"M Chan Park","year":"2021","unstructured":"Chan Park, M. et al. Varying outcomes among patients with large angiomyolipomas according to the treatment method. Urol. Int. 105, 680\u2013686 (2021).","journal-title":"Urol. Int."},{"key":"818_CR171","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2013.243","volume":"84","author":"KM Andrassy","year":"2013","unstructured":"Andrassy, K. M. Comments on \u2018KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 84, 622\u2013623 (2013).","journal-title":"Kidney Int."},{"key":"818_CR172","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.juro.2009.05.035","volume":"182","author":"A Kutikov","year":"2009","unstructured":"Kutikov, A. & Uzzo, R. G. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J. Urol. 182, 844\u2013853 (2009).","journal-title":"J. Urol."},{"key":"818_CR173","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1053\/ajkd.2002.32770","volume":"39","author":"JJ Bissler","year":"2002","unstructured":"Bissler, J. J., Racadio, J., Donnelly, L. F. & Johnson, N. D. Reduction of postembolization syndrome after ablation of renal angiomyolipoma. Am. J. Kidney Dis. 39, 966\u2013971 (2002).","journal-title":"Am. J. Kidney Dis."},{"key":"818_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22575\/interventionalradiology.2021-0015","volume":"8","author":"S Tsuchiya","year":"2023","unstructured":"Tsuchiya, S. et al. Prophylactic steroids for preventing postembolization syndrome after transcatheter arterial embolization of renal angiomyolipoma: a comparative study. Interv. Radiol. 8, 1\u20136 (2023).","journal-title":"Interv. Radiol."},{"key":"818_CR175","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/j.1464-410X.2006.06702.x","volume":"99","author":"A Minervini","year":"2007","unstructured":"Minervini, A. et al. Simple enucleation for the treatment of renal angiomyolipoma. BJU Int. 99, 887\u2013891 (2007).","journal-title":"BJU Int."},{"key":"818_CR176","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/003655900750016850","volume":"34","author":"SK Yip","year":"2000","unstructured":"Yip, S. K., Tan, P. H., Cheng, W. S., Li, M. K. & Foo, K. T. Surgical management of angiomyolipoma: nephron-sparing surgery for symptomatic tumour. Scand. J. Urol. Nephrol. 34, 32\u201335 (2000).","journal-title":"Scand. J. Urol. Nephrol."},{"key":"818_CR177","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1089\/end.2021.0165","volume":"36","author":"D Whiting","year":"2022","unstructured":"Whiting, D. et al. Complications after radical nephrectomy according to age: analysis from the British Association of Urological Surgeons nephrectomy audit. J. Endourol. 36, 188\u2013196 (2022).","journal-title":"J. Endourol."},{"key":"818_CR178","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1464-410X.2009.08649.x","volume":"105","author":"P Sooriakumaran","year":"2010","unstructured":"Sooriakumaran, P. et al. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int. 105, 101\u2013106 (2010).","journal-title":"BJU Int."},{"key":"818_CR179","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/1078-0432.CCR-18-1833","volume":"25","author":"MH Voss","year":"2019","unstructured":"Voss, M. H. et al. PTEN expression, not mutation status in TSC1, TSC2, or mTOR, correlates with the outcome on everolimus in patients with renal cell carcinoma treated on the randomized RECORD-3 trial. Clin. Cancer Res. 25, 506\u2013514 (2019).","journal-title":"Clin. Cancer Res."},{"key":"818_CR180","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/1535-7163.MCT-19-0642","volume":"19","author":"AH Nassar","year":"2020","unstructured":"Nassar, A. H. et al. Mutations and response to rapalogs in patients with metastatic renal cell carcinoma. Mol. Cancer Ther. 19, 690\u2013696 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"818_CR181","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-15-2631","volume":"22","author":"DJ Kwiatkowski","year":"2016","unstructured":"Kwiatkowski, D. J. et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 22, 2445\u20132452 (2016).","journal-title":"Clin. Cancer Res."},{"key":"818_CR182","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/ijc.32579","volume":"146","author":"JM Roldan-Romero","year":"2020","unstructured":"Roldan-Romero, J. M. et al. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. Int. J. Cancer 146, 1435\u20131444 (2020).","journal-title":"Int. J. Cancer"},{"key":"818_CR183","first-page":"1201","volume":"149","author":"J Bjornsson","year":"1996","unstructured":"Bjornsson, J., Short, M. P., Kwiatkowski, D. J. & Henske, E. P. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am. J. Pathol. 149, 1201\u20131208 (1996).","journal-title":"Am. J. Pathol."},{"key":"818_CR184","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1072-y","volume":"14","author":"S Auvin","year":"2019","unstructured":"Auvin, S. et al. A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report. Orphanet J. Rare Dis. 14, 91 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"818_CR185","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35168-y","volume":"8","author":"A Fujimoto","year":"2018","unstructured":"Fujimoto, A. et al. Establishment of a regional interdisciplinary medical system for managing patients with tuberous sclerosis complex (TSC). Sci. Rep. 8, 16747 (2018).","journal-title":"Sci. Rep."},{"key":"818_CR186","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/epi.12722","volume":"55","author":"EA Thiele","year":"2014","unstructured":"Thiele, E. A., Granata, T., Matricardi, S. & Chugani, H. T. Transition into adulthood: tuberous sclerosis complex, Sturge-Weber syndrome, and Rasmussen encephalitis. Epilepsia 55, 29\u201333 (2014).","journal-title":"Epilepsia"},{"key":"818_CR187","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/0883073819886244","volume":"35","author":"L McGarry","year":"2020","unstructured":"McGarry, L., Messer, R., Cree-Green, M., Ray, K. & Knupp, K. Incidence of hypertension among children treated with adrenocorticotropic hormone (ACTH) or prednisolone for infantile spasms. J. Child Neurol. 35, 215\u2013220 (2020).","journal-title":"J. Child Neurol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00818-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00818-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00818-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T09:07:00Z","timestamp":1716368820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00818-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":187,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["818"],"URL":"https:\/\/doi.org\/10.1038\/s41581-024-00818-0","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"8 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.S. is a Proctor for Intuitive Surgical System. D.J.K. has had research contracts with Genentech, AADI, and Revolution Medicines and has been a consultant to Genentech, AADI, Guidepoint, Bridgebio and Slingshot Insights. J.B.L. receives honorarium as an advisory board member for Novartis, Astellas, Pfizer, Roche, and Merck and is a consultant to Janssen. Bristol Myers Squibb conducts research at the centre that employs J.B.L. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}